T2 Biosystems and Clinicians to Share Clinical Data in Integrated Symposium and Poster Presentations at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Additionally, seven leading clinicians and users of T2Direct Diagnostics™ will offer scientific presentations during ECCMID that will highlight the most recent scientific data on the Company’s
“I have seen firsthand how the rapid detection of bacterial and fungal pathogens with T2Direct Diagnostics can improve patient outcomes, better manage broad-spectrum antimicrobial usage and combat antibiotic resistance,” said
The T2Bacteria and T2Candida Panels are able to identify sepsis-causing pathogens within 3 to 5 hours directly from whole blood, instead of days required with blood culture based diagnostics. This gives clinicians actionable information much earlier than was previously possible, allowing them to make more informed treatment plans for escalation or de-escalation of antimicrobial therapy.
Dr. Clancy continued, “When diagnosing and treating infectious diseases, time is of the essence. I am proud to be one of the clinicians here at ECCMID using T2Direct Diagnostics and believe that we must continue to spread awareness about this rapid diagnostic technology to improve patient care.”
Integrated Symposium
- “Rapid Diagnostics Direct from Whole Blood: A Solution for Fast and Appropriate Antimicrobial Therapy,” on
Monday, April 15 from16:00-18:00 CET in Hall D; presenters include:
• Prof.Michael Bauer , MD,Jena University (Jena,Germany )
• Dr.Cornelius (Neil) Clancy ,University of Pittsburgh Medical Center (Pittsburgh, PA )
• Dr.Giulia De Angelis ,Institute of Microbiology , Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli (Rome, Italy )
• Dr.Thomas Walsh ,New York Presbyterian Hospital (New York, NY )
Poster Presentations
- Development of a highly sensitive assay for the detection of carbapenem-resistance genes from whole blood by T2 magnetic resonance, on
Sunday, April 14 , from13:30-14:30 CET (Tom Lowery ) - Real-life diagnostic performance of T2Candida among ICU patients with risk factors for invasive candidiasis, on
Tuesday, April 16 from12:30-13:30 CET (Maiken Arendrup) - The T2Bacteria assay is a sensitive and rapid detector of bacteraemia that can be initiated in the emergency department and has potential to favourably influence subsequent therapy, on
Tuesday, April 16 from12:30-13:30 CET (Christopher Voigt ) The T2Bacteria Panel is a rapid detector of bacteraemia and has potential to guide therapy in patients with haematological malignancies and haematopoietic stem cell transplantation: a pilot study of non-culture molecular diagnosis, onTuesday, April 16 from12:30-13:30 CET (Thomas J. Walsh )- Evaluation of a molecular technology magnetic resonance for the direct identification of pathogens from blood samples in paediatric patients with suspected sepsis, on
Tuesday, April 16 from12:30-13:30 CET (Paola Bernaschi)
About T2 Biosystems
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
+1 610-455-2763
Investor Contact:
zkubow@w2ogroup.com
415-658-6436
Source: T2 Biosystems, Inc.